CN105308038B - Zeste增强子同源物2的抑制剂 - Google Patents
Zeste增强子同源物2的抑制剂 Download PDFInfo
- Publication number
- CN105308038B CN105308038B CN201480033093.6A CN201480033093A CN105308038B CN 105308038 B CN105308038 B CN 105308038B CN 201480033093 A CN201480033093 A CN 201480033093A CN 105308038 B CN105308038 B CN 105308038B
- Authority
- CN
- China
- Prior art keywords
- methyl
- oxo
- dihydropyridin
- dimethyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(C)OC(N[C@](CC1)CC[C@]1C(*)N(C)OC)=O Chemical compound CC(C)(C)OC(N[C@](CC1)CC[C@]1C(*)N(C)OC)=O 0.000 description 27
- CQZPEBDZIWYWEL-UHFFFAOYSA-N Cc1c(N)[s]cc1C(OC)=O Chemical compound Cc1c(N)[s]cc1C(OC)=O CQZPEBDZIWYWEL-UHFFFAOYSA-N 0.000 description 2
- RQHHTQQZIPZYKU-DVZOWYKESA-N C/C=C(/CCN1CCOCC1)\c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 Chemical compound C/C=C(/CCN1CCOCC1)\c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 RQHHTQQZIPZYKU-DVZOWYKESA-N 0.000 description 1
- WEWBQPFPCRBHDO-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=O Chemical compound CC(C)(C)OC(N(CC1)CC1c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=O WEWBQPFPCRBHDO-UHFFFAOYSA-N 0.000 description 1
- MNCXGBBUODZXES-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1c1c(C)c(C(OC)=O)c[s]1)=O Chemical compound CC(C)(C)OC(N(CC1)CC1c1c(C)c(C(OC)=O)c[s]1)=O MNCXGBBUODZXES-UHFFFAOYSA-N 0.000 description 1
- HFPTVKCVVCVGRX-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c1c(C)c(C(OC)=O)c[s]1)O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c1c(C)c(C(OC)=O)c[s]1)O)=O HFPTVKCVVCVGRX-UHFFFAOYSA-N 0.000 description 1
- PCJPGNCABBDNJU-UHFFFAOYSA-N CC(C=C(C)N1)=C(CN)C1=O Chemical compound CC(C=C(C)N1)=C(CN)C1=O PCJPGNCABBDNJU-UHFFFAOYSA-N 0.000 description 1
- RQSIAANKDQCDHF-UHFFFAOYSA-N CC(CCC1)N1c1c(C)c(C(OC)=O)c[s]1 Chemical compound CC(CCC1)N1c1c(C)c(C(OC)=O)c[s]1 RQSIAANKDQCDHF-UHFFFAOYSA-N 0.000 description 1
- WQHDTHDJPDGYLZ-UHFFFAOYSA-N CC(N1)=CC(C(F)(F)F)=C(CN)C1=O Chemical compound CC(N1)=CC(C(F)(F)F)=C(CN)C1=O WQHDTHDJPDGYLZ-UHFFFAOYSA-N 0.000 description 1
- LQRSUXVZQNCRKZ-JHJOSGQCSA-N CCC([C@H](CC1)CC[C@@H]1N)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 Chemical compound CCC([C@H](CC1)CC[C@@H]1N)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 LQRSUXVZQNCRKZ-JHJOSGQCSA-N 0.000 description 1
- QWQOUCCBLMVBJR-YGQOYYDZSA-N CCC([C@H](CC1)CC[C@@H]1NC(OC(C)(C)C)=O)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 Chemical compound CCC([C@H](CC1)CC[C@@H]1NC(OC(C)(C)C)=O)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 QWQOUCCBLMVBJR-YGQOYYDZSA-N 0.000 description 1
- XSSOURWDDVTNJJ-TZYNXQCKSA-N CCCN(CCO)C(C)c1c(C)c(C(NC/C(/C(C)=O)=C(\C)/C=C(/C)\N)=O)c[s]1 Chemical compound CCCN(CCO)C(C)c1c(C)c(C(NC/C(/C(C)=O)=C(\C)/C=C(/C)\N)=O)c[s]1 XSSOURWDDVTNJJ-TZYNXQCKSA-N 0.000 description 1
- IELCIYCNIFXFHZ-UHFFFAOYSA-N CCN(C(CC1)CCC1N(C)C)c1c(C)c(C(NCC2=C(C)C=C(C)N(C)C2=N)=N)c[s]1 Chemical compound CCN(C(CC1)CCC1N(C)C)c1c(C)c(C(NCC2=C(C)C=C(C)N(C)C2=N)=N)c[s]1 IELCIYCNIFXFHZ-UHFFFAOYSA-N 0.000 description 1
- YYYMQDRNWZMSCA-UHFFFAOYSA-N CCN(C1CCOCC1)C(C1)=C(C)C(C(OC)=O)=C1Cl Chemical compound CCN(C1CCOCC1)C(C1)=C(C)C(C(OC)=O)=C1Cl YYYMQDRNWZMSCA-UHFFFAOYSA-N 0.000 description 1
- WAUYOOANGDXOEM-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C)[s]1 WAUYOOANGDXOEM-UHFFFAOYSA-N 0.000 description 1
- LXCAZKRXHNGVNM-UHFFFAOYSA-N CCN(CCC(C)C(C(C1C)SC=C1C(NCC1=C(C)C=C(C)NC1=O)=O)O)C(O)OC(C)(C)C Chemical compound CCN(CCC(C)C(C(C1C)SC=C1C(NCC1=C(C)C=C(C)NC1=O)=O)O)C(O)OC(C)(C)C LXCAZKRXHNGVNM-UHFFFAOYSA-N 0.000 description 1
- YTCDDVHOZLILNH-OKILXGFUSA-N CCN([C@H](CC1)CC[C@H]1N(C)C)c1c[s]c(C(OC)=O)c1C Chemical compound CCN([C@H](CC1)CC[C@H]1N(C)C)c1c[s]c(C(OC)=O)c1C YTCDDVHOZLILNH-OKILXGFUSA-N 0.000 description 1
- IDRCVWWYENNMTH-HNNXBMFYSA-N CC[C@@H](c1c(C)c(C(OC)=O)c[s]1)N(CC1)CC=C1N(C)C Chemical compound CC[C@@H](c1c(C)c(C(OC)=O)c[s]1)N(CC1)CC=C1N(C)C IDRCVWWYENNMTH-HNNXBMFYSA-N 0.000 description 1
- MQSUJFMBRLFJQD-OAHLLOKOSA-N CC[C@H](c1c(C)c(C(OC)=O)c[s]1)N(CC1)CCC1N(C)C Chemical compound CC[C@H](c1c(C)c(C(OC)=O)c[s]1)N(CC1)CCC1N(C)C MQSUJFMBRLFJQD-OAHLLOKOSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N CN(CC1)CCC1=O Chemical compound CN(CC1)CCC1=O HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817436P | 2013-04-30 | 2013-04-30 | |
| US61/817,436 | 2013-04-30 | ||
| US201361842038P | 2013-07-02 | 2013-07-02 | |
| US61/842,038 | 2013-07-02 | ||
| US201361907024P | 2013-11-21 | 2013-11-21 | |
| US61/907,024 | 2013-11-21 | ||
| US201461936460P | 2014-02-06 | 2014-02-06 | |
| US61/936,460 | 2014-02-06 | ||
| PCT/IB2014/061012 WO2014177982A1 (en) | 2013-04-30 | 2014-04-25 | Enhancer of zeste homolog 2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105308038A CN105308038A (zh) | 2016-02-03 |
| CN105308038B true CN105308038B (zh) | 2018-05-29 |
Family
ID=50877537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480033093.6A Expired - Fee Related CN105308038B (zh) | 2013-04-30 | 2014-04-25 | Zeste增强子同源物2的抑制剂 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9505745B2 (enExample) |
| EP (1) | EP2991980B1 (enExample) |
| JP (1) | JP6373973B2 (enExample) |
| KR (1) | KR20160003115A (enExample) |
| CN (1) | CN105308038B (enExample) |
| AU (1) | AU2014261075B2 (enExample) |
| BR (1) | BR112015027527A2 (enExample) |
| CA (1) | CA2910873A1 (enExample) |
| CL (1) | CL2015003200A1 (enExample) |
| DO (1) | DOP2015000270A (enExample) |
| EA (1) | EA030196B1 (enExample) |
| ES (1) | ES2717680T3 (enExample) |
| HK (1) | HK1214815A1 (enExample) |
| MX (1) | MX2015015144A (enExample) |
| NZ (1) | NZ630205A (enExample) |
| PE (1) | PE20151981A1 (enExample) |
| PH (1) | PH12015502414A1 (enExample) |
| SG (1) | SG11201508203TA (enExample) |
| WO (1) | WO2014177982A1 (enExample) |
| ZA (1) | ZA201507398B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013120104A2 (en) * | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| US9505745B2 (en) * | 2013-04-30 | 2016-11-29 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| ES2640386T3 (es) | 2013-07-10 | 2017-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Potenciador de inhibidores del homólogo Zeste 2 |
| PL3102568T3 (pl) | 2014-02-06 | 2019-01-31 | Heptares Therapeutics Limited | Bicykliczne związki aza w postaci agonistów receptorów muskarynowych m1 |
| CN107148419A (zh) * | 2014-10-28 | 2017-09-08 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| AR102767A1 (es) * | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US20190070188A1 (en) * | 2015-11-06 | 2019-03-07 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
| DK3378859T3 (da) | 2015-11-19 | 2020-01-20 | Jiangsu Hengrui Medicine Co | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin |
| SG11201809560QA (en) * | 2016-05-05 | 2018-11-29 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
| US20170337814A1 (en) * | 2016-05-20 | 2017-11-23 | Donald Edward Morgan | Safety alerting drivers device and system |
| US10968215B2 (en) | 2016-09-07 | 2021-04-06 | Shanghai Haihe Pharmaceutical Co., Ltd. | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof |
| US20190367457A1 (en) | 2016-12-30 | 2019-12-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| NZ766447A (en) | 2018-01-31 | 2021-12-24 | Mirati Therapeutics Inc | Prc2 inhibitors |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| WO2020219448A1 (en) | 2019-04-22 | 2020-10-29 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| SG11202110085TA (en) * | 2019-05-31 | 2021-10-28 | Sichuan Haisco Pharmaceutical Co Ltd | Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof |
| JP7541538B2 (ja) | 2019-06-05 | 2024-08-28 | ミラティ セラピューティクス，インク． | 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| CN110964200A (zh) * | 2019-12-19 | 2020-04-07 | 新纳奇材料科技江苏有限公司 | 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法 |
| WO2021129629A1 (zh) * | 2019-12-23 | 2021-07-01 | 四川海思科制药有限公司 | Zeste增强子同源物2抑制剂及其用途 |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2012142513A1 (en) * | 2011-04-13 | 2012-10-18 | Epizyme, Inc. | Substituted benzene compounds |
| CN102970869A (zh) * | 2010-05-07 | 2013-03-13 | 葛兰素史密斯克莱有限责任公司 | 吲哚 |
| WO2013049770A2 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1708697A4 (en) * | 2004-01-30 | 2007-11-28 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| RU2006138036A (ru) * | 2004-03-30 | 2008-05-10 | Чирон Корпорейшн (Us) | Производные замещенного тиофена в качестве противораковых средств |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な６員ヘテロ環 |
| US9023847B2 (en) * | 2009-08-07 | 2015-05-05 | Merck Patent Gmbh | Azaheterocyclic compounds |
| JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013120104A2 (en) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| IL296199B2 (en) | 2012-04-13 | 2024-12-01 | Eisai R&D Man Co Ltd | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| US9505745B2 (en) * | 2013-04-30 | 2016-11-29 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
-
2014
- 2014-04-25 US US14/787,866 patent/US9505745B2/en not_active Expired - Fee Related
- 2014-04-25 ES ES14727619T patent/ES2717680T3/es active Active
- 2014-04-25 NZ NZ630205A patent/NZ630205A/en not_active IP Right Cessation
- 2014-04-25 WO PCT/IB2014/061012 patent/WO2014177982A1/en not_active Ceased
- 2014-04-25 CN CN201480033093.6A patent/CN105308038B/zh not_active Expired - Fee Related
- 2014-04-25 CA CA2910873A patent/CA2910873A1/en not_active Abandoned
- 2014-04-25 AU AU2014261075A patent/AU2014261075B2/en not_active Ceased
- 2014-04-25 KR KR1020157033651A patent/KR20160003115A/ko not_active Ceased
- 2014-04-25 MX MX2015015144A patent/MX2015015144A/es unknown
- 2014-04-25 BR BR112015027527A patent/BR112015027527A2/pt not_active IP Right Cessation
- 2014-04-25 PE PE2015002298A patent/PE20151981A1/es not_active Application Discontinuation
- 2014-04-25 SG SG11201508203TA patent/SG11201508203TA/en unknown
- 2014-04-25 HK HK16102708.1A patent/HK1214815A1/zh unknown
- 2014-04-25 EA EA201592068A patent/EA030196B1/ru not_active IP Right Cessation
- 2014-04-25 JP JP2016511152A patent/JP6373973B2/ja not_active Expired - Fee Related
- 2014-04-25 EP EP14727619.0A patent/EP2991980B1/en active Active
-
2015
- 2015-10-06 ZA ZA2015/07398A patent/ZA201507398B/en unknown
- 2015-10-19 PH PH12015502414A patent/PH12015502414A1/en unknown
- 2015-10-30 DO DO2015000270A patent/DOP2015000270A/es unknown
- 2015-10-30 CL CL2015003200A patent/CL2015003200A1/es unknown
-
2016
- 2016-10-13 US US15/292,200 patent/US9790212B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| CN102970869A (zh) * | 2010-05-07 | 2013-03-13 | 葛兰素史密斯克莱有限责任公司 | 吲哚 |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2012142513A1 (en) * | 2011-04-13 | 2012-10-18 | Epizyme, Inc. | Substituted benzene compounds |
| WO2013049770A2 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2910873A1 (en) | 2014-11-06 |
| EA030196B1 (ru) | 2018-07-31 |
| JP6373973B2 (ja) | 2018-08-15 |
| BR112015027527A2 (pt) | 2017-07-25 |
| PE20151981A1 (es) | 2016-01-14 |
| EA201592068A1 (ru) | 2016-05-31 |
| ES2717680T3 (es) | 2019-06-24 |
| JP2016517878A (ja) | 2016-06-20 |
| HK1214815A1 (zh) | 2016-08-05 |
| US9790212B2 (en) | 2017-10-17 |
| PH12015502414A1 (en) | 2016-02-22 |
| US20170029412A1 (en) | 2017-02-02 |
| US20160102083A1 (en) | 2016-04-14 |
| AU2014261075A1 (en) | 2015-11-05 |
| EP2991980A1 (en) | 2016-03-09 |
| ZA201507398B (en) | 2017-01-25 |
| US9505745B2 (en) | 2016-11-29 |
| CL2015003200A1 (es) | 2016-04-22 |
| NZ630205A (en) | 2017-03-31 |
| MX2015015144A (es) | 2016-02-18 |
| DOP2015000270A (es) | 2016-02-15 |
| EP2991980B1 (en) | 2019-01-02 |
| SG11201508203TA (en) | 2015-11-27 |
| WO2014177982A1 (en) | 2014-11-06 |
| KR20160003115A (ko) | 2016-01-08 |
| AU2014261075B2 (en) | 2017-01-19 |
| CN105308038A (zh) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105308038B (zh) | Zeste增强子同源物2的抑制剂 | |
| CN104968646B (zh) | Zeste同源物增强子2的抑制剂 | |
| CN109563043B (zh) | 作为dnmt1的抑制剂的取代的吡啶 | |
| CN102970869B (zh) | 吲哚 | |
| JP5889875B2 (ja) | アザインダゾール | |
| CN107148419A (zh) | Zeste增强子同源物2抑制剂 | |
| CN105452246A (zh) | Zeste增强子同源物2的抑制剂 | |
| CN102917588A (zh) | 化合物 | |
| CN105473580A (zh) | Zeste同源物增强子2抑制剂 | |
| CN107849032A (zh) | Zeste增强子同源物2抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180529 Termination date: 20210425 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |